ANCA Associated Vasculitis
35
12
16
4
Key Insights
Highlights
Success Rate
57% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.6%
3 terminated out of 35 trials
57.1%
-29.4% vs benchmark
11%
4 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (35)
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
PR3-AAV Resilient Remission or PRRR
Hydroxychloroquine in ANCA Vasculitis Evaluation
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
A Study of RD06-04 in Patients With Active Autoimmune Diseases
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
Soluble CD95 Ligand Role in the Pathophysiology of Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
Early-access Avacopan in Real-world ANCA-associated Vasculitis
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis